Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit Without GVHD

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2015.11.945
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

CIK: A Path to GVL Without GVHD?

Biology of Blood and Marrow Transplantation
TransplantationHematology
2011English

26 in Vitro Cultured Allogeneic Cytotoxic T Cells Mediate GVL Without Systemic GVHD Despite Expression of Functional LPAM.

Pediatric Research
Child HealthPediatricsPerinatology
2006English

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80

Frontiers in Immunology
AllergyImmunology
2018English

Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Chronic GVHD Induced GVL Effect After Unmanipulated Haploidentical Hematopoietic SCT for AML and Myelodysplastic Syndrome

Bone Marrow Transplantation
TransplantationHematology
2014English

Ibrutinib Therapy for Lymphoplasmacytic Lymphoma

American Journal of Hematology
Hematology
2017English

Novel Approaches in GVHD Therapy

Bone Marrow Transplantation
TransplantationHematology
2005English

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

British Journal of Haematology
Hematology
2018English

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy